A tripeptide fragment of alpha-MSH researched for potent anti-inflammatory signaling with minimal pigmentary activity.
Pre-loaded with a typical KPV vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for KPV. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 200 mcg – 500 mcg | daily | subcutaneous | Commonly cited secondary research-protocol ranges for subcutaneous KPV Informal research schedules often land in the low-to-mid hundreds of mcg daily; these are not formal labeled doses. |
| Not a fixed mcg value | study-defined | model-dependent | Experimental IBD and inflammation models (route varies: oral, i.p., or other study-defined routes) Animal papers use mg/kg or fixed mcg schedules specific to the model. Cite methods rather than scaling blindly. |
People searching this page also look for: kpv peptide dosage, kpv peptide dosage chart, kpv peptide dosage per day, kpv peptide dosage protocol, kpv peptide injection dosage, kpv peptide dosage recommendations, kpv peptide dosage calculator, kpv peptide recommended dosage.
KPV is the carboxyl-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone. Classical pharmacology work showed that this tiny fragment retains substantial anti-inflammatory activity associated with the parent hormone while avoiding much of the melanotropic baggage of full-length alpha-MSH.
Peer-reviewed studies have examined KPV in models of crystal-induced and cytokine-driven inflammation, keratinocyte signaling, and murine inflammatory bowel disease. Reviews of alpha-MSH-related peptides position KPV and related analogs as tool compounds for immunology and barrier-tissue research. Antimicrobial properties against selected organisms have also been explored in experimental systems.
Dosage education should emphasize that human standardized injectable regimens are not established the way they are for approved hormones. Ranges circulating in research-peptide communities are secondary references. This page uses research-use-only language and points readers to primary immunology papers for mechanism context.
KPV modulates inflammatory signaling with evidence for both melanocortin-related and receptor-independent actions in different experimental setups. Reported effects include reduced pro-inflammatory cytokine tone and interference with NF-kB-linked transcriptional programs in immune and epithelial cells. Because pigmentary MC1R-driven melanogenesis is largely dissociated from KPV's anti-inflammatory profile, researchers value it as a stripped-down probe of alpha-MSH immunomodulation. Barrier tissues, skin and gut mucosa, are recurring experimental contexts.
anti-inflammatory pharmacology · inflammatory bowel disease models · dermatologic inflammation · innate immune modulation · host-defense peptide research
Immunologists and gastroenterology labs use KPV in colitis and peritonitis models. Dermatology researchers examine keratinocyte and skin inflammation pathways. Peptide chemists compare KPV with related analogs such as KdPT. The audience is inflammation-biology focused rather than metabolic-obesity focused.
Keep lyophilized KPV cold, dry, and protected from light. Reconstitute with bacteriostatic water under clean technique, refrigerate, and use within supplier stability guidance for small peptides.
KPV is the component that distinguishes Klow from Glow when added to GHK-Cu + BPC-157 + TB-500. Researchers also examine it conceptually alongside other barrier-focused agents. Combination products still require independent dose math for KPV content.
The questions people actually search for, answered plainly.
Secondary research protocols commonly discuss roughly 200-500 mcg subcutaneously per day, but this is not a standardized approved regimen. Primary literature doses are model-specific. Use those papers for scientific work and treat community charts as provisional.
A 10 mg vial with 2 mL bac water yields 5 mg/mL (5,000 mcg/mL), so 0.05 mL delivers 250 mcg. Smaller peptides are easy to over-concentrate; pick a diluent volume that makes your target mcg land on whole insulin units.
Daily administration is the pattern most often repeated in informal research writeups. Split dosing appears less often than once-daily schedules. Confirm whether your blend already includes KPV before adding a standalone vial.
Example at 5 mg/mL: 4 units (0.04 mL) ~ 200 mcg; 5 units ~ 250 mcg; 10 units ~ 500 mcg on a U-100 syringe. Recalculate if your reconstitution differs.
In acute animal inflammation models, endpoints can be measured within hours to days. Chronic barrier-injury models run longer. Human timelines for research endpoints are not standardized on educational blogs.
As a three-amino-acid peptide, KPV is expected to clear quickly from plasma. Pharmacodynamic anti-inflammatory effects in tissues may outlast measurable plasma levels; quantitative human half-life data remain limited publicly.
Yes in the narrow sense that blend products already combine it with repair peptides. Scientifically, stacking should serve a hypothesis, for example inflammatory tone plus matrix repair, and each agent's mcg contribution must stay transparent.
Primary literature on KPV. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides